RxDoctor Payments Data

Samuel Brown

Family · Sneedville, TNNPI 1184038812

Payments from drug & device makers

$433in general payments, 2019–2025

Across 26 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$121
  • Novo Nordisk$63
  • Exact Sciences$35
  • Lilly USA, LLC$34
  • Vanda Pharmaceuticals Inc.$32
  • Axsome Therapeutics, Inc.$24
  • plus $124 from 7 others

What the payments were for

  • Food & beverage$433100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$433 in reported general payments places this provider in the 45th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$798
Medicare patients
28
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$41,474
OzempicSemaglutide23$40,175
EliquisApixaban40$39,763
JardianceEmpagliflozin37$39,242
TrulicityDulaglutide17$16,264
Spiriva RespimatTiotropium Bromide17$14,919
LinzessLinaclotide14$13,439
MounjaroTirzepatide13$13,151
Breo ElliptaFluticasone/Vilanterol14$12,119
InvokanaCanagliflozin16$9,243
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$8,364
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$6,255
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,206
SymbicortBudesonide/Formoterol Fumarate18$5,470
Albuterol Sulfate HfaAlbuterol Sulfate171$4,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$21$59,79964 claims
Novo NordiskOzempic$63$40,17523 claims
Lilly USA, LLCTrulicity, Mounjaro$34$29,41530 claims
AbbVieLinzess$121$13,43914 claims
Johnson & JohnsonInvokana$13$9,24316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 6,706 family providers in Tennessee.

Other family in Sneedville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →